Silence Therapeutics plc (NASDAQ:SLN) Position Increased by Boothbay Fund Management LLC

Boothbay Fund Management LLC lifted its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 105.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 351,527 shares of the company's stock after purchasing an additional 180,372 shares during the quarter. Boothbay Fund Management LLC owned about 1.17% of Silence Therapeutics worth $2,419,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at $26,000. Barclays PLC lifted its holdings in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after acquiring an additional 2,793 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after purchasing an additional 5,233 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Silence Therapeutics in the 4th quarter worth approximately $69,000. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock worth $74,000 after purchasing an additional 6,098 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 7th. Morgan Stanley decreased their target price on Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. The Goldman Sachs Group reduced their target price on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a report on Tuesday, March 4th. Finally, BMO Capital Markets dropped their price target on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

Silence Therapeutics Trading Down 2.0 %

NASDAQ SLN traded down $0.08 during trading on Friday, reaching $3.93. 423,543 shares of the company's stock were exchanged, compared to its average volume of 296,991. Silence Therapeutics plc has a fifty-two week low of $1.97 and a fifty-two week high of $24.38. The company's fifty day simple moving average is $3.47 and its 200-day simple moving average is $6.99. The firm has a market capitalization of $117.62 million, a PE ratio of -2.50 and a beta of 1.25.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.